阿尔茨海默病的发病机制和动物模型研究进展

摘要/Abstract

摘要： 阿尔茨海默病（Alzheimer's disease，AD）是一种慢性中枢神经系统退行性疾病。AD的病因不明、发病机制复杂，因此动物模型的建立对探索其发病机制及寻找防治疾病的药物具有重要作用。在动物模型中，转基因小鼠模型和转基因果蝇模型已成为研究热点。本文就阿尔茨海默病的发病机制和动物模型的研究现状进行综述。

关键词: 阿尔茨海默病, 发病机制, 动物模型, 转基因小鼠, 转基因果蝇

Abstract: Alzheimer's disease (AD) is a common neurodegenerative disease. The pathogenesis of AD is yet unclear and there is no satisfactory therapy for AD. AD transgenic models not only help to elucidate the pathogenesis of AD, but also provide potential screening models for drugs to treat the disease. At present, transgenic models have been regard as superior models for AD. In this review, we summarize the recent research progress on the pathogenesis of AD and transgenic models.

Key words: Alzheimer's disease, pathogenesis, animal model, transgenic mice, transgenic drosophila

中图分类号:

R965

刘红彬, 武海霞. 阿尔茨海默病的发病机制和动物模型研究进展[J]. 神经药理学报, 2013, 3(4): 14-22.

LIU Hong-bin，WU Hai-xia. Overview of the Pathogenesis and Animal Models of Alzheimer's Disease[J]. Acta Neuropharmacologica, 2013, 3(4): 14-22.

参考文献

[1] Alzheimer's Association. Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2012, 8(2): 131-168.

[2] Goedert M, Spillantini M G. A century of Alzheimer's disease[J] Science, 2006, 314(5800): 777-781.

[3] Zhao Guo-jun, Cui Mei-zhen, Mao Guo-zhang, et al. Gamma cleavage is dependent on zeta cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain[J]. J Biol Chem, 2005, 280(45):37689-37697.

[4] Thorlakur Jonsson, Jasvinder K Atwal, Stacy Steinberg, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline[J]. Nature, 2012, 488(7409):96-99.

[5] Kuo Yu-Min, Mark R Emmerling, Carmen Vigo-Pelfrey, et al. Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains[J]. J Bio Chem, 1996, 271(8):4077-4081.

[6] Dimitra G Georganopoulou, Chang Lei, Jwa-Min Nam, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease[J]. Proc Natl Acad Sci USA, 2005, 102 (7): 2273-2276.

[7] Igor Klyubin, Domminic M Walsh, Cynthia A Lemere, et al. Amyloid beta Protein immunotherapy neutralizes Abeta Oligomers that disrupt synaptic plasticity in vivo[J]. Nat Med, 2005, 11(5): 556-561.

[8] Bart Dermaut, Samir Kumar-Singh, Rosa Rademakers, et al. Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum[J]. Trends Genet, 2005, 21(12): 664-672.

[9] Carlo Ballatore, Virginia M-Y Lee, John Q Trojanowski. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders[J]. Nat Rev Neurosci, 2007, 8(9): 663-672.

[10] Town T, Nikolic V, Tan J. The microglial activation continuum from innate to adaptive responses [J]. Neuro Inflamation, 2005, 2 (24):1472-1483.

[11] Sofroniev M V, Peaison R C. Degeneration of cholineigic neurons in the basal nucleus following kainic or N-methyl-D-aspartic acid application to the cerebral cortex in die rat [J]. Brain Res, 1985, 339(1):186-190.

[12] Nabeshima T. Trial to produce animal model of Alzheimer's disease by continuous infusion of beta-amyloid protein into the rat cerebral ventricle [J]. Nihon Shinkei Seishin Yakurigaku Zasshi, 1995, 15(5): 411-418.

[13] Alvarez X A, Miguel-Hidalgo J J, Fernandez-Novoa L, et al. Intrahippocampal injections of the beta-amyloid 1-28 fragment induces behavioral deficits in rats [J]. Methods Find Exp Clin Phamacol, 1997, 19(7):471-479.

[14] Tian Q, Lin Z Q, Wang X C, et al．Injection of okadaic acid into the Meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit [J]. Neuroscience, 2004, 126(2): 277-284.

[15] Yin Yang-Yang, Liu Hao, Cong Xiao-Bin, et al．Acetyl-L-carnitine attenuates okadaic acid induced tau hyperphosphorylation and spatial memory impairment in rats [J]. J Alzheimer's Dis, 2010, 19(2):735-746.

[16] Joanna L Jankowsky, Linda H Younkin, Victoria Gonzales, et al. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice[J]. J Biol Chem, 2007, 282(31):22707-22720.

[17]Games D, Buttini M, Kobayashi D, et al. Mice as models: transgenic approaches and Alzheimer's disease [J]. J Alzheimers Dis, 2006, 9(3Suppl): 133-149.

[18] Charles Duyckaerts, Marie Claude Potier, Benoit Delatour. Alzheimer disease models and human neuropathology: similarities and differences [J]. Acta Neuropathol, 2008, 115(1):5-38.

[19] Martin C Herzig, David T Winkler, Patrick Burgermeister, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis [J]. Nat Neurosci, 2004, 7(9):954-960.

[20] Miao Jian-ting, Xu Feng, Davis Judianne, et al. Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein [J]. Am J Pathol, 2005, 167(2):505-515.

[21] Jada Lewis, Eileen McGowan, Julia Rockwood, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein[J]. Nat Genet, 2000, 25(4):402-405.

[22] Jurgen Gotz, Andreas Schild, Fred Hoemd1i, et al. Amyloid-induced neurofibrillary tangle formation in Alzheimer’s disease insight from transgenic mouse and tissue-culture models[J]. Int J Dev Neurosci, 2004, 22(7):453-465.

[23] Borchelt D R. Metabolism of presenilin 1: influence of presenilin 1 on amyloid precursor protein processing [J]. Neurobiol Aging, 1998, 19(1):15-18.

[24] Holly Oakley, Sarah L Cole, Sreemathi Logan, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation[J].J Neurosci, 2006, 26(40):10129-10140.

[25] Jada Lewis, Dennis W Dickson, Lin Wen-Lang, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP [J]. Science, 2001, 293(5534):1487-1491.

[26] Salvatore Oddo, Antonella Caccamo, Masashi Kitazawa, et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease [J]. Neurobiol Aging, 2003, 24(8):1063-1070.

[27] Aida Attar, Liu Ting-yu, Chan Wai-ting, et al. A shortened Barnes maze protocol reveals memory deficits at 4-months of age in the triple-transgenic mouse model of Alzheimer's disease [J]. J Pharm Pharmacol, 2013, 65(12):1753-1756.

[28] Sarantseva S V, Bolshakova O I, Timoshenko S I, et al. Studying pathogenesis of Alzheimer’s disease in a drosophila melanogaster model: human APP overexpression in the brain of transgenic flies leads to deficit of the synaptic protein synaptotagmin [J]. Genetika, 2009, 45(1): 119-126.

[29] Mark E Fortini, Nancy M Bonini. Modeling human neurodegenerative disease in drosophila[J]. Trends Genet, 2000, 16(4): 161-167.

[30] Tomonori Kurokawa, Shinji Asada, Shinobu Nishitani, et al. Age-related changes in manganese superoxide dismutase activity in the cerebral cortex of senescence-ccelerated prone and resistant mouse[J].Neurosci Lett, 2001, 298 (2):135-138.

[31] Yang Wei-na, Han Hua, Hu Xiao-dan, et al. The effects of perindopril on cognitive impairment induced by d-galactose and aluminum trichloride via inhibition of acetylcholinesterase activity and oxidative stress [J].Pharmacol Biochem Behav, 2013, 114:31-36.

[32] Walsh T J, Herzog C D, Gandhi C, et al. Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits [J].Brain Res, 1996, 726(1-2):69-79.

[33] Hanna Rosenmann, Nikolaos Grigoriadis, Dimitrios Karussis, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein [J]. Arch Neurol, 2006, 63(10):1459-14067.